Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SAP30 divergent transcript (SAP30-DT)
- Target
- SAP30-DT
- Molecular classification
- Long non-coding RNA (lncRNA), Divergent transcript
01
Overview
SAP30 divergent transcript (SAP30-DT) is a long non-coding RNA gene affiliated with the lncRNA class and classified as a divergent transcript, meaning it is situated near a protein-coding gene (SAP30) but transcribed in the opposite direction. It is also referenced as MIRE (c-Myc-induced regulator of ELF2), suggesting possible involvement in c-Myc-related transcriptional programs, but no mechanistic data or biological functions have been firmly established for the transcript itself. As a non-protein-coding RNA, SAP30-DT is not considered a classical therapeutic target such as a receptor, enzyme, transporter, or transcription factor. No drugs or biomarkers are associated with this gene, and its precise role in disease or cell biology remains to be elucidated.
- Other names
- MIREc-Myc-induced regulator of ELF2ENST00000608794ENSG00000272870
02
Mechanism of action
None known; not a druggable target; no approved or experimental drugs act via this lncRNA
03
Biological functions
Currently unclear; as a lncRNA, likely to be involved in gene regulation or chromatin organization; no direct biological functions established for SAP30-DT itself
04
Disease associations
No direct evidence for disease association or specific disease roles for SAP30-DT as distinct from SAP30
Beyond the preview
Go deeper on SAP30 divergent transcript (SAP30-DT).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAP30 divergent transcript (SAP30-DT).